Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/19/2026 | $10.00 | Buy | Maxim Group |
| 4/2/2024 | $8.00 | Neutral → Buy | Ladenburg Thalmann |
| 2/12/2024 | $14.00 | Buy | H.C. Wainwright |
6-K - Evaxion A/S (0001828253) (Filer)
6-K - Evaxion A/S (0001828253) (Filer)
6-K - Evaxion A/S (0001828253) (Filer)
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™. The award is another strong external validation and recognition of the AI-Immunology™ platform, which harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. The award was received by Evaxion CEO Helen-Tayton Martin at the Prix Galien UK Awards ceremony at the Natural History Museum in London. Evaxion and AI-Immunology
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing Poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conv
Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the functional characterization of EVX-04, an off-the-shelf therapeutic acute myeloid leukemia (AML) vaccine, in a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, June 11-14, 2026. The new preclinical data will represent another step towards clinical testing of EVX-04. Evaxion plans to submit a clinical trial application in the second half o
Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00
Ladenburg Thalmann upgraded Evaxion Biotech from Neutral to Buy and set a new price target of $8.00
H.C. Wainwright initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $14.00
3 - Evaxion A/S (0001828253) (Issuer)
3/A - Evaxion A/S (0001828253) (Issuer)
3/A - Evaxion A/S (0001828253) (Issuer)
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors. The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself. As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E
COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces
SC 13G - Evaxion Biotech A/S (0001828253) (Subject)
SC 13G/A - Evaxion Biotech A/S (0001828253) (Subject)
SC 13G - Evaxion Biotech A/S (0001828253) (Subject)
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion's strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the
Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di
COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo